Table 3 Crude and adjusted hazard ratios for the association between variable and the risk of NTM infection during all follow-up period
Univariate analysis | Model A | Model B | ||||
|---|---|---|---|---|---|---|
HR | (95%CI) | HR | (95%CI) | HR | (95%CI) | |
Group | ||||||
Non- SS | Reference | Reference | Reference | Reference | Reference | Reference |
SS | 7.66 | (2.36–24.94) | 3.17 | (0.70–14.24) | ||
SS treated without immunosuppressants | 2.47 | (0.31–19.53) | 1.95 | (0.24–15.68) | ||
SS treated with immunosuppressants | 25.45 | (6.88–94.05) | 17.77 | (4.53–69.61) | ||
Age | ||||||
< 50 years | Reference | Reference | Reference | Reference | Reference | Reference |
≥ 50 years | 1.82 | (0.50–6.60) | 1.63 | (0.43–6.19) | 1.64 | (0.43–6.24) |
Gender | ||||||
Female | Reference | Reference | Reference | Reference | Reference | Reference |
Male | 3.50 | (1.08–11.36) | 3.34 | (1.02–10.96) | 3.27 | (0.99–10.74) |
CCI group | ||||||
0 | Reference | Reference | Reference | Reference | Reference | Reference |
≥ 1 | 1.55 | (0.48–5.04) | 0.97 | (0.29–3.30) | 1.00 | (0.30–3.41) |
Medications | ||||||
Immunosuppressants | 13.74 | (3.78–49.94) | 4.89 | (0.94–25.33) | ||
Methotrexate | 18.74 | (4.15–84.56) | ||||
Azathioprin | 21.26 | (4.71–95.91) | ||||
Cyclophosphamide | 27.86 | (6.18–125.70) | ||||
Steroid | 3.94 | (1.08–14.37) | 2.65 | (0.68–10.26) | 2.72 | (0.70–10.55) |